Highest-materiality recent filing
Aura Q1 net loss $33.7M; Phase 3 CoMpass enrollment mid-2026; new CEO appointed
Net loss of $33.7M in Q1 2026; R&D expenses $28.0M (up from $23.3M) reflecting Phase 3 costs.
Aura Biosciences raises ~$280.8M in public offering; to repurchase $39M in stock from Matrix Capital
Offering of 39,591,000 shares at $6.00 and 3,800,000 pre-funded warrants, net proceeds ~$280.8M.
New CEO Natalie Holles, former CEO of Third Harmonic Bio and Audentes, appointed effective April 30, 2026.
Enters stock purchase agreement to repurchase up to 6,922,870 shares from Matrix Capital Master Fund at $5.64 per share, matching equity offering price.
Aura Biosciences reports 2025 net loss $106.2M; Phase 3 CoMpass enrollment to complete mid-2026
Cash and equivalents $144.2M as of Dec 31, 2025; sufficient to fund operations into Q1 2027.
Aura Biosciences Q3 net loss $26.1M; Phase 3 CoMpass data expected Q4 2027
Net loss of $26.1M in Q3 2025 vs $21.0M in Q3 2024; R&D expenses rose to $22.2M from $17.0M.
Aura Biosciences closes $69.9M public offering of common stock and warrants
Sold 11.7M shares, 3.6M pre-funded warrants, and 3.8M common stock warrants at $4.90 combined price.
Net loss $27.5M for Q1 2025 vs $19.7M in Q1 2024; R&D expenses rose to $23.3M from $17.1M.
Net loss $86.9M in FY2024 vs $76.4M in FY2023; R&D expenses $73.3M.
Aura Biosciences Q3 net loss $21M; cash $174.4M; Phase 3 CoMpass authorized in Europe
Net loss $21.0M (Q3 2024) vs $18.5M YoY; cash $174.4M funds operations into 2H 2026.
Phase 1 trial of bel-sar in NMIBC: 4 of 5 low-grade patients had complete response (no tumor cells on histopathology).
CFO Julie Feder to depart Oct 25; VP Finance Amy Elazzouzi named interim CFO
CFO Julie Feder will resign effective Oct 25, 2024; no dispute or disagreement with company.
Aura reports positive Phase 2 bel-sar results: 80% tumor control, 90% vision preservation
Bel-sar achieved 80% tumor control rate in Phase 3-eligible patients (8/10); complete cessation of growth post-treatment.
Aura Biosciences reports Q2 2024 net loss of $20.3M; cash $187.4M into H2 2026
Net loss of $20.3M in Q2 2024 vs $18.3M in Q2 2023; R&D spend $16.9M, G&A $5.9M.
Aura Biosciences reports FY2023 net loss $76.4M; Phase 3 CoMpass trial enrolling with FDA SPA
Cash and equivalents $226.2M as of Dec 31, 2023; expected to fund operations into H2 2026.
Aura Biosciences raises $99M in public offering; Q3 net loss $18.5M
Closed underwritten public offering of 11M shares at $9.00/share, gross proceeds $99.0M; net proceeds ~$92.6M.
FDA agreed under Special Protocol Assessment to design and planned analysis of CoMpass Phase 3 trial for bel-sar in early-stage choroidal melanoma.
Aura Biosciences names new CMO/President of R&D and CTO; CMO Rich transitions to advisor
J. Jill Hopkins appointed CMO and President of R&D, effective Oct 16, 2023; prior roles at Novartis, Gyroscope, Roche-Genentech.
Cash and marketable securities $173.5M as of March 31, 2023; cash runway into 2025.
Net loss of $58.8M for FY2022 vs $35.3M in 2021; cash & securities $188.8M sufficient into 2025.
100% tumor control (8/8) and 88% visual acuity preservation in patients receiving three cycles of bel-sar.
Aura Biosciences raises $86.7M in public offering of 7.7M shares at $12.00/share
Net proceeds of ~$86.7M from 7.705M shares (including full overallotment) at $12.00 per share.
Net loss $15.9M for Q3 2022 vs $8.8M YoY; cash $111.5M sufficient into 2024.
Interim Phase 2 data for belzupacap sarotalocan (AU-011) in early-stage choroidal melanoma show 88.9% (8/9) tumor control rate at therapeutic regimen.
Aura Biosciences receives FDA Fast Track for belzupacap sarotalocan in NMIBC; Phase 1 trial H2 2022
FDA granted Fast Track designation for belzupacap sarotalocan (AU-011) for treatment of Non-Muscle Invasive Bladder Cancer.
Belzupacap sarotalocan showed statistically significant vision preservation at 2 years vs. plaque radiotherapy (logMAR p=0.0094).
Aura Biosciences Q1 2022 net loss $12.8M; cash $133.3M; AU-011 pivotal trial in 2H 2022
Net loss of $12.8M in Q1 2022 compared to $5.9M in Q1 2021; cash and marketable securities $133.3M, sufficient into 2024.
Aura Biosciences reports FY2021 net loss $35.3M; cash $149.1M into 2024
Net loss for FY2021 was $35.3M, up from $22.2M in FY2020; R&D expenses rose to $25.2M.
Aura Biosciences Q3 net loss $8.8M; AU-011 data and IPO highlight quarter
Net loss $8.8M for Q3 2021 vs $3.6M YoY; R&D expenses $6.4M (up from $2.9M).
On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the “Effective Date”), to fill the newly created vacancy.
Dr. Elisabet de los Pinos, the Company’s founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date
notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date
the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026
Appointment of Chief Financial and Business Officer Effective as of May 13, 2025 (the “Effective Date”), the Board of Directors of the Company appointed Anthony Gibney as the Company’s Chief Financial and Business Officer.
Beginning on the Effective Date, Amy Elazzouzi, the Company’s Senior Vice President, Finance, will cease serving as the Company’s principal financial officer and continue as the Company’s principal accounting officer and Mr. Gibney will serve as the Company’s principal financial officer.
unanimously appointed Teresa Marie Bitetti, MBA, as a Class II director, effective March 31, 2025
On September 25, 2024, the Board of Directors of the Company (the “Board”) designated Amy Elazzouzi, the Company’s Vice President, Finance, as the Company’s interim principal financial officer and interim principal accounting officer, in each case, effective on the Transition Date, to serve in such roles during the pendency of the Company’s search for a new Chief Financial Officer.
On September 23, 2024, Julie Feder notified Aura Biosciences, Inc. (the “Company”) of her departure from her role at the Company as an employee and Chief Financial Officer, effective as of October 25, 2024 (the “Transition Date”).
On April 12, 2024, Raj Parekh, Ph.D., notified Aura Biosciences, Inc. (the “Company”) of his intention to resign as a member of the Company’s board of directors (the “Board”), effective on June 20, 2024, the date of the Company’s 2024 annual meeting of stockholders.
J. Jill Hopkins, M.D., will serve as the Company’s Chief Medical Officer and President of Research & Development, effective as of October 16, 2023
On April 3, 2023, Mark De Rosch informed Aura Biosciences, Inc. (the “Company”) of his intent to resign as Chief Operating Officer of the Company. Mr. De Rosch’s resignation will be effective on April 30, 2023.
Max materiality 0.90 · Median 0.60 · Most common event other_material